A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 192
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : MuSK
Long Form : muscle-specific tyrosine kinase
No. Year Title Co-occurring Abbreviation
2021 Characterization of LRP4/Agrin Antibodies From a Patient With Myasthenia Gravis. CMAP, Ig, MG, NMJ
2021 Clinical and pathophysiologic relevance of autoantibodies in neonatal myasthenia gravis. AChR, IVIG, MG, MuSK-MG
2021 Disease severity and response to treatment in Iranian patients with myasthenia gravis. MG
2021 MuSK-positive myasthenia may be triggered not only by SARS-CoV-2. BiPAP, CPAP, MG
2021 Myasthenia gravis associated with anti-MuSK antibodies developed after SARS-CoV-2 infection. CBA, MG, RIA
2021 Secreted Signaling Molecules at the Neuromuscular Junction in Physiology and Pathology. AChRs, CMS, CTGF, FGF, LRP4, NMJ
2020 Affinity maturation is required for pathogenic monovalent IgG4 autoantibody development in myasthenia gravis. mAbs, MG, UCAs
2020 Agrin Influences Botulinum Neurotoxin A-Induced Nerve Sprouting via miR-144-agrin-MuSK Signaling. BoNT
2020 Antigen specific B cells in myasthenia gravis patients. AChR, LRP4, MG
10  2020 Autoantibodies in Japanese patients with ocular myasthenia gravis. Abs, AChR, CBAs, LRP4, MG, OMG
11  2020 Effects of Teriflunomide on B Cell Subsets in MuSK-Induced Experimental Autoimmune Myasthenia Gravis and Multiple Sclerosis. CFA, EAMG, MG, MS
12  2020 Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis. Ab, MG, MM, MuSK-IgG, RTX
13  2020 Management of Juvenile Myasthenia Gravis. AChR, JMG
14  2020 MuSK EAMG: Immunological Characterization and Suppression by Induction of Oral Tolerance. MG, NMJs
15  2020 MuSK-Associated Myasthenia Gravis: Clinical Features and Management. MG
16  2020 Myasthenia gravis with anti-muscle-specific tyrosine kinase antibodies during therapy for multiple myeloma: a case report. MM
17  2020 Myasthenia Gravis with Anti-Muscle-Specific Tyrosine Kinase Antibody during Pregnancy and Risk of Neonatal Myasthenia Gravis: A Case Report and Review of the Literature. Ab, MG, MuSK-MG, TNMG
18  2020 Myasthenia Gravis: From the Viewpoint of Pathogenicity Focusing on Acetylcholine Receptor Clustering, Trans-Synaptic Homeostasis and Synaptic Stability. ACh, CRD, Lrp4, MG, NMJ
19  2020 Roles of cytokines and T cells in the pathogenesis of myasthenia gravis. AChR, IL, MG, Treg
20  2020 Subgroup stratification and outcome in recently diagnosed generalized myasthenia gravis. MG
21  2020 Therapeutic and Diagnostic Challenges in Myasthenia Gravis. MG
22  2020 Use of rituximab in muscle-specific tyrosine kinase antibody-positive myasthenia gravis: Preliminary observations from a tertiary care center in Northern India. MG
23  2019 Association between musk antibody concentrations and the myasthenia gravis composite score in 3 patients: A marker of relapse? Ab, MGC
24  2019 Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients. AChR, mAbs, MG
25  2019 Clinical features and outcomes of patients with myasthenia gravis. AChR, dSN, MG
26  2019 Congenital myasthenic syndrome due to mutations in MUSK suggests that the level of MuSK phosphorylation is crucial for governing synaptic structure. AChR
27  2019 High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria. Ab, AChR, MG, RTX
28  2019 Knee osteoarthritis induces atrophy and neuromuscular junction remodeling in the quadriceps and tibialis anterior muscles of rats. ACLT, KOA, MuRF1, nAChR, NCAM, NMJs, TA
29  2019 [Distribution characteristics and correlation analysis of antibody detection value in myasthenia gravis]. AChE, AChR, ELISA, MG, MGFA, RyR
30  2018 Anti-MuSK Antibody-positive Myasthenia Gravis Successfully Treated with Outpatient Periodic Weekly Blood Purification Therapy. MG, PE
31  2018 HLA and MuSK-positive myasthenia gravis: A systemic review and meta-analysis. MG
32  2018 Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis. MG
33  2018 Myasthenia gravis seronegative for acetylcholine receptor antibodies in South Korea: Autoantibody profiles and clinical features. AChR, CBA, LRP4, MG, RIPA
34  2018 Quality of life in patients with MuSK positive myasthenia gravis. AChR, MG, QoL
35  2018 Serological Immunoglobulin-Free Light Chain Profile in Myasthenia Gravis Patients. Abs, AChR, FLCs, MG, RTX
36  2017 Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis. AChR, MG
37  2017 B cells in the pathophysiology of myasthenia gravis. AChR, MG
38  2017 Diagnostic utility of cortactin antibodies in myasthenia gravis. AChR, dSNMG, MG
39  2017 Electrical stimulation delays reinnervation in denervated rat muscle. DOK7, ES, nAChR, NCAM, NMJ
40  2017 Immunization with Recombinantly Expressed LRP4 Induces Experimental Autoimmune Myasthenia Gravis in C57BL/6 Mice. AChR, EAMG, LRP4, MG, NMJ
41  2017 Is MuSK myasthenia gravis linked to IgG4-related disease? Ab, Ig, MG
42  2017 Non-neuronal cholinergic activity is potentiated in myasthenia gravis. ACh, MG, PBMCs, QMG
43  2017 Repetitive Nerve Stimulation in MuSK-Antibody-Positive Myasthenia Gravis. Ab, AChR, DSN, MG, RNS
44  2017 Rituximab treatment of myasthenia gravis: A systematic review. AChR, MG, MM
45  2016 Anti-MuSK myasthenia gravis with prolonged remission. MG
46  2016 Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin. AChR, dSNMG, LRP4, MG
47  2016 Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. AChR, LRP4, MG
48  2016 Denervation versus pre- and postsynaptic muscle immobilization: Effects On acetylcholine- and muscle-specific tyrosine kinase receptors. AChRs
49  2016 Double Seronegative Myasthenia Gravis with Anti-LRP4 Antibodies Presenting with Dropped Head and Acute Respiratory Insufficiency. AChR, LRP4, MG
50  2016 Dynein disruption perturbs post-synaptic components and contributes to impaired MuSK clustering at the NMJ: implication in ALS. AChRs, ALS, NMJ
51  2016 Electrophysiological findings in patients with low density lipoprotein receptor related protein 4 positive myasthenia gravis. AChR, LRP4, MG, RNS
52  2016 Fatigue in myasthenia gravis: risk factors and impact on quality of life. ADL, CF, MG, MG-ADL, MG-QoL, QoL
53  2016 Muscle-Specific Receptor Tyrosine Kinase (MuSK) Myasthenia Gravis. AChR, MG, NMJ
54  2016 Myopathic changes detected by quantitative electromyography in patients with MuSK and AChR positive myasthenia gravis. AChR, EMG, MG
55  2016 R-spondin 2 promotes acetylcholine receptor clustering at the neuromuscular junction via Lgr5. AChR, Lgr5, LRP4, NMJ, RSPO2, SMN
56  2016 Roles of collagen Q in MuSK antibody-positive myasthenia gravis. AChE, AChR, ColQ, LRP4, MG, NMJ
57  2016 The Myotonic Plot Thickens: Electrical Myotonia in Antimuscle-Specific Kinase Myasthenia Gravis. ---
58  2015 An oncogenic role of Agrin in regulating focal adhesion integrity in hepatocellular carcinoma. HCC
59  2015 An update on laboratory diagnosis in myasthenia gravis. AChR, LEMS, LRP-4
60  2015 An update on laboratory diagnosis in myasthenia gravis. AChR, LEMS, LRP-4
61  2015 Anti-MuSK Antibody-positive Myasthenia Gravis Mimicking Amyotrophic Lateral Sclerosis. ALS, MG
62  2015 Association of HLA class II (DRB1, DQA1, DQB1) alleles and haplotypes with myasthenia gravis and its subgroups in the Iranian population. AChR, MG
63  2015 Characterization of B cells in muscle-specific kinase antibody myasthenia gravis. MG
64  2015 Collagen Q--a potential target for autoantibodies in myasthenia gravis. AChE, AChR, CBA, ColQ, LRP4, MG, NMJ, SNMG
65  2015 Dental follicle mesenchymal stem cell administration ameliorates muscle weakness in MuSK-immunized mice. AChR, DFMSC, EAMG, MG, MSC, NMJ
66  2015 Flow Cytofluorimetric Analysis of Anti-LRP4 (LDL Receptor-Related Protein 4) Autoantibodies in Italian Patients with Myasthenia Gravis. AChR, dSN, LRP4, MG
67  2015 Impaired Synaptic Development, Maintenance, and Neuromuscular Transmission in LRP4-Related Myasthenia. CMS, EPP, EPs, LRP4
68  2015 Mouse models of myasthenia gravis. ---
69  2015 Polyclonal neural cell adhesion molecule antibody prolongs the effective duration time of botulinum toxin in decreasing muscle strength. BTXA, NCAM, P-NCAM-Ab, RT-PCR, WB
70  2014 Altered active zones, vesicle pools, nerve terminal conductivity, and morphology during experimental MuSK myasthenia gravis. EPCs, MG, NMJs
71  2014 Anti-agrin autoantibodies in myasthenia gravis. AChR, LRP4, MG
72  2014 Clinical and Electrophysiologic Responses to Acetylcholinesterase Inhibitors in MuSK-Antibody-Positive Myasthenia Gravis: Evidence for Cholinergic Neuromuscular Hyperactivity. AChEIs, DIP, MG, NT, PB, R-CMAPs
73  2014 Clinical and scientific aspects of muscle-specific tyrosine kinase-related myasthenia gravis. ---
74  2014 Diagnostic approach to diplopia. ---
75  2014 Electrophysiological profile of the patients with MuSK positive myasthenia gravis. AChR, EDC, MCD, MG, OO, RNS
76  2014 Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis. MG
77  2014 High frequency of DQB1*05 and absolute absence of DRB1*13 in muscle-specific tyrosine kinase positive myasthenia gravis. HLA, MG, OR
78  2014 HnRNP C, YB-1 and hnRNP L coordinately enhance skipping of human MUSK exon 10 to generate a Wnt-insensitive MuSK isoform. AChR
79  2014 Infantile anti-MuSK positive myasthenia gravis in a patient with autoimmune polyendocrinopathy type 3. AChR, MG
80  2014 Myasthenia gravis and Lambert-Eaton myasthenic syndrome. MG
81  2014 Myopathy, muscle atrophy and tongue lipid composition in MuSK myasthenia gravis. AChR, EMG, MG
82  2014 Serum high mobility group box 1 is upregulated in myasthenia gravis. AChR, HMGB1, MG
83  2014 The MuSK activator agrin has a separate role essential for postnatal maintenance of neuromuscular synapses. NMJ
84  2014 The presence of dysautonomia in different subgroups of myasthenia gravis patients. AChR, BRS, HRV, MG
85  2014 Treatment of MuSK-Associated Myasthenia Gravis. ACEi, AChR, MG, MMG
86  2014 [Autoantibodies detected in acetylcholine receptor antibody-negative myasthenia gravis]. Abs, AChR, LRP4, MG
87  2013 APP interacts with LRP4 and agrin to coordinate the development of the neuromuscular junction in mice. AChR, LRP4, NMJ
88  2013 COOH-terminal collagen Q (COLQ) mutants causing human deficiency of endplate acetylcholinesterase impair the interaction of ColQ with proteins of the basal lamina. AChE, BL, BME, ColQ, EP, NMJ
89  2013 IGF-1 antibody prolongs the effective duration time of botulinum toxin in decreasing muscle strength. BTX-A, GAP43, IGFBP5, PCRs
90  2013 MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters. AChRs, LRP4, MG
91  2013 MuSK-Ab positive myasthenia: not always grave. Abs, IS, MG
92  2013 Myasthenia gravis: an update for the clinician. LRP4, MG
93  2013 The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis. ---
94  2013 Thymus histology and concomitant autoimmune diseases in Japanese patients with muscle-specific receptor tyrosine kinase-antibody-positive myasthenia gravis. AChR, MG
95  2013 What's in the literature? ALS
96  2013 [Novel autoantibodies in myasthenia gravis]. Abs, ColQ, Kv1.4, LRP4, MG
97  2012 AchR-positive myasthenia gravis with MRI evidence of early muscle atrophy. AChR, MG
98  2012 An ocular form of myasthenia gravis with a high titer of anti-MuSK antibodies during a long-term follow-up. MG
99  2012 Antibodies against Wnt receptor of muscle-specific tyrosine kinase in myasthenia gravis. AChR, CRD, MG
100  2012 HLA-DQA1*03:02/DQB1*03:03:02 is strongly associated with susceptibility to childhood-onset ocular myasthenia gravis in Southern Han Chinese. AChR, DQ2, MG, SBT